相关实验视频
Updated: Jul 19, 2025

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice
Published on: March 17, 2014
梅波利祖马布在过敏性支气管肺性阿斯伯吉洛斯症中,因感染而复杂
Toru Hamada1, Tomoya Katsuta1, Kento Aibara1
1Respiratory Medicine, Ehime Prefectural Central Hospital, Matsuyama, Ehime, 790-0024, Japan.
过敏性支气管肺性阿斯伯吉洛症 (ABPA) 用类固醇治疗可能会导致感染. 梅波利祖马布为患有传染性并发症的ABPA患者提供了有效的替代方案,证明了早期引入的好处.
科学领域:
- 肺部病理学 肺部病理学
- 过敏学 过敏学
- 传染性疾病 传染性疾病
背景情况:
- 过敏性支气管肺性阿斯伯吉洛症 (ABPA) 是对阿斯伯吉洛菌的过敏反应.
- 目前的治疗方法,如类固醇和抗真菌药物有风险,包括感染和药物相互作用.
研究的目的:
- 为了评估mepolizumab在患有ABPA并发症多次感染的患者中的疗效.
主要方法:
- 一名71岁妇女的病例报告,发现了ABPA,乙型肝炎,型肝炎和细菌液.
- 最初使用口服类固醇治疗,随后因传染性并发症而转换为mepolizumab.
主要成果:
- 梅波利祖马布在患者治疗过程的早期被引入.
- 转换为梅波利祖马布是由于类固醇使用引起的众多传染性并发症所必需的.
结论:
- 早期服用梅波利祖马布可以有效地管理ABPA,特别是当感染性疾病复杂时.
- 这一案例突出了mepolizumab作为在特定ABPA患者群体中长期类固醇治疗的潜在替代品.
更多相关视频
10:26P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives
Published on: June 15, 2020
09:52Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis
Published on: March 9, 2018
相关概念视频
Pneumonia III: Complications and Assessment
COPD: Management Using Bronchodilators and Corticosteroids
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD: